Executive Summary
An expert team
Ground-breaking technology with broad applications
Protectable, broad-spectrum therapeutics
An ideal candidate for drug combinations
IP allows for further innovations
Ready for clinical phase
Tranexamic Technologies
Antiviral Technologies, LLC
Anti-Plasmin Technologies, LLC
Murdock Technologies, LLC
Tranexamic Technologies, LLC
Tranexamic Technologies designates a group of affiliated companies managed by two medical industry entrepreneurs with deep experience in new product identification and development. We have assembled a team of experts from academia, clinical practice, private labs, and professional organizations to develop new therapies based on the intersection of certain fundamental biological activities and previously unexamined mechanisms of action available to an existing small molecule.
The initial agent being tested is Tranexamic Acid (TA), a synthetic lysine analog created to provide antifibrinolysis. It is often recognized that electrostatic bonds between proteins are an essential part of many biological activities, but our findings led us to explore the benefits of using agents capable of antagonizing those bonds, with significant implications in a very broad range of medical issues, including inhibition of viral and other microbial infections, cancer, and other diseases. (For further information, see Areas of Focus.)
Through inspiration
Through inspiration and years of research, we have uncovered these novel benefits of TA, and several significant applications are ready for clinical study. Although TA is generic in some forms, we have protected our position through extensive new patent filings on methods of use and compositions of synthetic lysine analogs, new analogs and derivatives, creation of novel methods of administration, and combinations with other compounds.
Because of TA’s direct and secondary benefits with respect to various diseases, its outstanding safety record, and its various mechanisms of action, it makes an excellent candidate to combine with other drugs, which is one of the successful trends of the pharmaceutical industry for a number of reasons.
TA’s multiple MOAs, its excellent safety record, our testing thus far, and the underlying science give the new forms and uses of TA multiple avenues to improve patient care.
We invite discussions with licensees, acquirors, or financial partners regarding combinations as well as further development and commercialization of our technologies.
